ClinicalTrialsFinder

EGFR Positive Non-small Cell Lung Cancer Clinical Trials

0 recruiting

Showing 1–2 of 2 trials

Recruiting
Phase 2

Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification

EGFR Positive Non-small Cell Lung CancerMET Amplification
Qingdao Central Hospital60 enrolled1 locationNCT07322783
Recruiting

Osimertinib for Advanced EGFR-positive NSCLC Patients

EGFR Positive Non-small Cell Lung Cancer
National University Hospital, Singapore58 enrolled1 locationNCT05037331